Nutraceuticals: 

Nutraceutical Protocols to Complement Chronic Opioid Therapy

Based on current medical literature, a multimodal nutraceutical approach stratified by pain phenotype can be developed to complement chronic opioid therapy. By doing so, nutraceuticals can be applied in ways that will enhance analgesic benefits of opioids as well as reducing the buildup of tolerance and opioid-induced hyperalgesia.

 

See:  

Nutraceutical Protocols: 

 

 

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

Nutraceutical approaches to complement chronic opioid therapy

Section I

When considering the addition of nutraceuticals for the management of chronic pain in patients on chronic opioid therapy, one must establish approaches that take into account the mechanistic processes in which interaction with opioids can be advantageous.

   The evidence supports targeting four key mechanistic processes [1][2]:

  1. Oxidative stress
  2. Neuroinflammation
  3. NMDA receptor modulation
  4. Descending pathway enhancement.

Pain Phenotype Classification for Nutraceutical Selection

Additionally, the approach should be tailored based on the predominant pain mechanism:

  1. Inflammatory/Nociceptive Pain (e.g., osteoarthritis, inflammatory arthritis, musculoskeletal pain)
  2. Neuropathic Pain (e.g., diabetic neuropathy, radiculopathy, post-herpetic neuralgia)
  3. Nociplastic Pain/Central Sensitization (e.g., fibromyalgia, chronic widespread pain, chronic primary pain)
  4. Mixed Pain States (combinations of the above, common in chronic pain populations)

1. Core Nutraceutical Regimen (All Pain Types)

These agents address the fundamental mechanisms of opioid tolerance and opioid-induced hyperalgesia and should be considered as a foundation for all patients on chronic opioid therapy:

  1. Palmitoylethanolamide (PEA): Ultramicronized formulation, 600 mg twice daily for 3 weeks, then 600 mg daily. PEA has the strongest clinical evidence for opioid co-administration, delaying tolerance to morphine, tramadol, and oxycodone while reducing spinal glial activation. A meta-analysis of 18 RCTs (1,196 patients) confirmed efficacy across nociceptive, neuropathic, and nociplastic pain types.[1][2][3]
  2. Magnesium: 400–500 mg elemental magnesium daily (glycinate or citrate forms for bioavailability). Magnesium enhances opioid analgesia through NMDA receptor antagonism and restores the MOR-NMDAR complex. Clinical trials confirm reduced opioid consumption without increased side effects.[4][5]
  3. Melatonin: 3–10 mg at bedtime. Melatonin demonstrates strong evidence for opioid synergy by decreasing NLRP3 inflammasome activation and enhancing descending modulation via MT2 receptor-mediated recruitment of mu-opioid receptors in the ventrolateral PAG.[6][7]

Add-on Nutraceuticals for Specific Phenotypes

   Inflammatory/Nociceptive Pain

  • Curcumin: High-bioavailability formulation (BCM-95 or Theracumin), 500 mg three times daily. Meta-analysis demonstrates significant pain reduction comparable to NSAIDs in osteoarthritis with fewer adverse events. Curcumin attenuates opioid tolerance by inhibiting CaMKIIα activity.[8][9][3]
  • Omega-3 Fatty Acids (EPA/DHA): 1–2 g daily. A 2025 meta-analysis of 41 RCTs showed moderate pain reduction (SMD −0.55) with benefits increasing over 6 months, particularly for rheumatoid arthritis and mixed chronic pain. Omega-3s produce additive antinociceptive effects with morphine and attenuate tolerance development.[10][11][12]
  • Boswellia serrata: 300–500 mg standardized extract three times daily. Effective for osteoarthritis with demonstrated reduction in NSAID and gabapentinoid use by 22–24%.[13][14][15]

   Neuropathic Pain

  • Alpha-Lipoic Acid (ALA): 600 mg daily (can increase to 600 mg twice daily). Systematic reviews support efficacy in diabetic polyneuropathy, reducing total symptom scores including stabbing pain, burning, and paresthesias. ALA inhibits morphine tolerance by reducing oxidative stress and suppressing iNOS expression, with effects enhanced by concurrent NAC.[16][17][18]
  • Acetyl-L-Carnitine (ALC): 500–1000 mg twice daily. Evidence supports use in diabetic peripheral neuropathy. Combined with ultramicronized PEA in a 1:1 ratio, ALC demonstrates superior anti-inflammatory and antinociceptive effects.[16][19]
  • Vitamin D3: Optimize to serum 25(OH)D levels of 40–60 ng/mL. Vitamin D modulates opioid signaling by regulating expression of endogenous opioid precursors (Pdyn, Penk, Pomc).[20][21]

   Nociplastic Pain/Central Sensitization

This phenotype requires emphasis on central mechanisms and descending modulation. Guidelines recommend non-pharmacological approaches as first-line, with opioids ideally avoided due to reduced efficacy and serious risks.[21]

  • Melatonin: Higher doses (5–10 mg) may be beneficial given the central mechanisms involved.
  • Resveratrol: 150–500 mg daily. Attenuates morphine tolerance through AMPK activation suppressing microglial activation, SIRT1 upregulation, and NMDA receptor downregulation.[14][19][22]
  • NAC (N-Acetyl Cysteine): 600–1200 mg twice daily. Restores glutamate transporter GLT-1 levels and reduces oxidative stress in the nucleus accumbens, potentially helping prevent opioid dependence and craving.[18][23][4]
  • Dietary modification: Low-saturated fat, low-added sugar dietary pattern to reduce neuroinflammation and central sensitization via gut-brain axis modulation.[15]

 

Recommended Tiered Implementation

Tier

Agents

Rationale

References

TIER 1

ALL PATIENTS

PEA 600 mg BID → QD, Magnesium 400 mg QD, Melatonin 3–5 mg QHS

Core tolerance prevention and opioid synergy

[1], [2], [3], [4]

TIER 2

INFLAMMATION

Add: Curcumin 500 mg TID, Omega-3 1–2 g QD

Peripheral inflammation reduction

[5], [6], [7]

TIER 2

NEUROPATHIC

Add: ALA 600 mg QD-BID, ALC 500 mg BID, Vitamin D3

Oxidative stress reduction, nerve support

[8], [9], [10], [11]

TIER 2

NOCIPLASTIC

Add: Resveratrol 250 mg QD, NAC 600 mg BID

Central sensitization modulation

[10], [12], [13], [14]

TIER 3

REFRACTORY

Consider:  Sulforaphane, Quercetin, Taurine

Additional pathway targeting

[5], [15], [16]

Safety Considerations

   These nutraceuticals have favorable safety profiles:

  • PEA showed no adverse effects across multiple studies.[3][26]
  • Alpha Lipoic Acid (ALA at doses ≥1200 mg/day may cause nausea and vomiting.[19]
  • Curcumin demonstrated fewer withdrawals due to adverse events compared to NSAIDs.[8]
  • Magnesium should be used cautiously in renal impairment.

Potential pharmacokinetic interactions with opioids are minimal for these agents, though curcumin may affect CYP3A4 metabolism at high doses.[27][11]

Important Caveats

The evidence base is predominantly preclinical for direct opioid-nutraceutical interactions, with clinical trials specifically evaluating these combinations in chronic opioid patients remaining limited.[1][28] Translation from preclinical findings requires caution, and individual patient response may vary. This approach should complement, not replace, standard multimodal pain management including physical therapy, psychological interventions, and appropriate pharmacotherapy.

 

Section II

Nutraceutical Dosing Protocols for Patients on Chronic Opioid Therapy

Core Regimen for All Pain Types on Chronic Opioid Therapy

Nutraceutical

Dosing Protocol

Key Considerations

References

Palmitoylethanolamide (PEA)

600 mg BID × 3 weeks, then 600 mg QD maintenance; use ultramicronized formulation

Ultramicronized form has superior bioavailability and crosses blood-brain barrier; effects seen within 4–6 weeks

[1], [2], [3], [4]

Magnesium

400–600 mg elemental magnesium daily (glycinate or citrate preferred)

Avoid in renal impairment (CrCl 30); toxicity risk >5000 mg/day; GI intolerance common with oxide form

[5], [6], [7]

Melatonin

3–10 mg at bedtime; start low and titrate based on response

Mean tolerated dose in trials ~12 mg/day; favorable safety profile; transient benefits on sleep and pain at 3 weeks

[8], [9], [10]

Add-Ons:

Inflammatory/Nociceptive Pain (Add-Ons)

Nutraceutical

Dosing Protocol

Key Considerations

References

Curcumin

High-bioavailability formulation: BCM-95 500 mg TID, or Theracumin 180 mg daily

Standard curcumin has poor bioavailability; BCM-95 has ~7× greater bioavailability; comparable to NSAIDs with fewer adverse events

[1], [2], [3], [4]

Omega-3 (EPA/DHA)

1–2 g combined EPA/DHA daily; lower doses (≤1.35 g/day) may be more effective

Benefits increase over 6 months; effective for RA, migraine, mixed chronic pain; less effective for OA

[5], [6], [7]

Boswellia serrata

100–300 mg enriched extract BID (standardized to 30% AKBA)

Improvements seen within 5 days; 90-day treatment optimal; well-tolerated

[8], [9], [10], [11]

 

Neuropathic Pain (Add-Ons)

Nutraceutical

Dosing Protocol

Key Considerations

References

Alpha-Lipoic Acid (ALA)

600 mg once daily (optimal risk-benefit); can increase to 600 mg BID

Doses ≥1200 mg/day associated with nausea/vomiting/vertigo; effective for diabetic polyneuropathy symptoms

[1], [2], [3], [4]

Acetyl-L-Carnitine (ALC)

500–1000 mg BID

Synergistic with PEA in 1:1 ratio; evidence in diabetic neuropathy

[Document]

Vitamin D3

Dose to achieve 25(OH)D levels 40–60 ng/mL; typically 2000–5000 IU daily

Check baseline levels; modulates opioid gene expression

[Document]

Nociplastic Pain/Central Sensitization (Add-Ons)

Nutraceutical

Dosing Protocol

Key Considerations

References

Resveratrol

500 mg daily

Significant IL-6 reduction at ≥500 mg/day; reduces TNF-α; clinical trial results mixed for OA

[1], [2], [3]

N-Acetylcysteine (NAC)

600 mg BID; can increase to 1200 mg BID

Well-tolerated up to 3000 mg/day; GI symptoms possible; restores glutamate homeostasis

[4], [5], [6]

—

IMPLEMENTATION PROTOCOL

Phase 1: Initiation (Weeks 1–4)

  • Start with core regimen: PEA 600 mg BID + Magnesium 400 mg daily + Melatonin 3 mg QHS
  • Assess baseline pain levels, sleep quality, and opioid requirements

Phase 2: Phenotype-Specific Addition (Weeks 4–8)

Add phenotype-specific agents based on predominant pain mechanism:

  • For inflammatory pain: Add curcumin + omega-3
  • For neuropathic pain: Add ALA + ALC + optimize vitamin D
  • For nociplastic pain: Add resveratrol + NAC; emphasize sleep optimization with higher melatonin doses

Phase 3: Optimization (Weeks 8–12)

  • Assess response: pain scores, functional status, opioid requirements
  • Transition PEA to maintenance dosing (600 mg QD) if responding
  • Consider adding tier 3 agents (sulforaphane, quercetin, taurine) for refractory cases

 

   References for Section I

  1. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
  2. Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
  3. Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis. Gatti A, Lazzari M, Gianfelice V, et al. Pain Medicine (Malden, Mass.). 2012;13(9):1121-30. doi:10.1111/j.1526-4637.2012.01432.x.
  4. Efficacy and Safety of Magnesium for the Management of Chronic Pain in Adults: A Systematic Review. Park R, Ho AM, Pickering G, et al. Anesthesia and Analgesia. 2020;131(3):764-775. doi:10.1213/ANE.0000000000004673.
  5. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. Chou R, Fanciullo GJ, Fine PG, et al. The Journal of Pain. 2009;10(2):113-30. doi:10.1016/j.jpain.2008.10.008.
  6. A Systematic Review and Meta-Analysis on the Role of Nutraceuticals in the Management of Neuropathic Pain in in Vivo Studies. Ilari S, Proietti S, Russo P, et al. Antioxidants (Basel, Switzerland). 2022;11(12):2361. doi:10.3390/antiox11122361.
  7. Exploring Mechanistic Insights by Carotenoids in Neuropathic and Inflammatory Pain. Abbaszadeh F, Jorjani M, Amirian R, Fakhri S, Khan H. Current Neuropharmacology. 2025;:CN-EPUB-149147. doi:10.2174/011570159X371386250619064416.
  8. The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
  9. The Analgesic Effect of Curcumin and Nano-Curcumin in Clinical and Preclinical Studies: A Systematic Review and Meta-Analysis. Hajimirzaei P, Eyni H, Razmgir M, et al. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;398(1):393-416. doi:10.1007/s00210-024-03369-0.
  10. Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
  11. Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs. Heiskanen T, Kalso E. Current Pharmaceutical Design. 2012;18(37):6079-89. doi:10.2174/138161212803582423.
  12. Implications of Opioid Analgesia for Medically Complicated Patients. Smith H, Bruckenthal P. Drugs & Aging. 2010;27(5):417-33. doi:10.2165/11536540-000000000-00000.
  13. From Fibrositis to Fibromyalgia to Nociplastic Pain: How Rheumatology Helped Get Us Here and Where Do We Go From Here?. Clauw DJ. Annals of the Rheumatic Diseases. 2024;83(11):1421-1427. doi:10.1136/ard-2023-225327.
  14. Bioactive Compounds for Neuropathic Pain: An Update on Preclinical Studies and Future Perspectives. Shen CL, Castro L, Fang CY, et al. The Journal of Nutritional Biochemistry. 2022;104:108979. doi:10.1016/j.jnutbio.2022.108979.
  15. Nutritional Intervention in Chronic Pain: An Innovative Way of Targeting Central Nervous System Sensitization?. Nijs J, Tumkaya Yilmaz S, Elma Ö, et al. Expert Opinion on Therapeutic Targets. 2020;24(8):793-803. doi:10.1080/14728222.2020.1784142.
  16. The Role of Diet and Non-Pharmacologic Supplements in the Treatment of Chronic Neuropathic Pain: A Systematic Review. Frediani JK, Lal AA, Kim E, et al. Pain Practice : The Official Journal of World Institute of Pain. 2024;24(1):186-210. doi:10.1111/papr.13291.
  17. Evaluation of the Analgesic Effect of Ɑ-Lipoic Acid in Treating Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G. Pharmacological Research. 2022;177:106075. doi:10.1016/j.phrs.2022.106075.
  18. Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain. Viana MDM, Lauria PSS, Lima AA, et al. Antioxidants (Basel, Switzerland). 2022;11(12):2420. doi:10.3390/antiox11122420.
  19. Nutraceutical Approach to Peripheral Neuropathies: Evidence From Clinical Trials. Mostacci B, Liguori R, Cicero AF. Current Drug Metabolism. 2018;19(5):460-468. doi:10.2174/1389200218666171031145419.
  20. Mechanistic Insight Into the Effects of Curcumin on Neuroinflammation-Driven Chronic Pain. Hasriadi, Dasuni Wasana PW, Vajragupta O, Rojsitthisak P, Towiwat P. Pharmaceuticals (Basel, Switzerland). 2021;14(8):777. doi:10.3390/ph14080777.
  21. Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Lancet (London, England). 2021;397(10289):2098-2110. doi:10.1016/S0140-6736(21)00392-5.
  22. Efficacy of a Combination of N-Palmitoylethanolamide, Beta-Caryophyllene, Carnosic Acid, and Myrrh Extract on Chronic Neuropathic Pain: A Preclinical Study. Fotio Y, Aboufares El Alaoui A, Borruto AM, et al. Frontiers in Pharmacology. 2019;10:711. doi:10.3389/fphar.2019.00711.
  23. Non-Drug Pain Relievers Active on Non-Opioid Pain Mechanisms. Marchesi N, Govoni S, Allegri M. Pain Practice : The Official Journal of World Institute of Pain. 2022;22(2):255-275. doi:10.1111/papr.13073.
  24. Diet Composition’s Effect on Chronic Musculoskeletal Pain: A Narrative Review. Kurapatti M, Carreira D. Pain Physician. 2023;26(7):527-534.
  25. New Concepts of Chronic Pain and the Potential Role of Complementary Therapies. Wojcikowski K, Vigar VJ, Oliver CJ. Alternative Therapies in Health and Medicine. 2020;26(S1):18-31.
  26. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-Analysis. Paladini A, Fusco M, Cenacchi T, et al. Pain Physician. 2016;19(2):11-24.
  27. Drug Interactions of Clinical Significance With Opioid Analgesics. Maurer PM, Bartkowski RR. Drug Safety. 1993;8(1):30-48. doi:10.2165/00002018-199308010-00005.
  28. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.

   References for Section II

  1. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
  2. Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
  3. Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis. Gatti A, Lazzari M, Gianfelice V, et al. Pain Medicine (Malden, Mass.). 2012;13(9):1121-30. doi:10.1111/j.1526-4637.2012.01432.x.
  4. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-Analysis. Paladini A, Fusco M, Cenacchi T, et al. Pain Physician. 2016;19(2):11-24.
  5. Efficacy and Safety of Magnesium for the Management of Chronic Pain in Adults: A Systematic Review. Park R, Ho AM, Pickering G, et al. Anesthesia and Analgesia. 2020;131(3):764-775. doi:10.1213/ANE.0000000000004673.
  6. Management of Headache (2023). Jane Abanes PhD DNP MSN/Ed PMHCNS PMHNP-BC RN, Natasha M. Antonovich PharmD BCPS, Andrew C. Buelt DO, et al. Department of Veterans Affairs.
  7. A Double-Blinded Randomised Controlled Study of the Value of Sequential Intravenous and Oral Magnesium Therapy in Patients With Chronic Low Back Pain With a Neuropathic Component. Yousef AA, Al-deeb AE. Anaesthesia. 2013;68(3):260-6. doi:10.1111/anae.12107.
  8. Melatonin for Neuropathic Pain: A Double-Blind, Placebo-Controlled, Randomized, Crossover Trial. Gilron I, Elkerdawy H, Tu D, et al. Pain. 2025;:00006396-990000000-00905. doi:10.1097/j.pain.0000000000003651.
  9. Melatonin Treatment Has Consistent but Transient Beneficial Effects on Sleep Measures and Pain in Patients With Severe Chronic Pain: The DREAM-CP Randomised Controlled Trial. Onyeakazi UM, Columb MO, Rosalind A, Kanakarajan S, Galley HF. British Journal of Anaesthesia. 2024;132(4):725-734. doi:10.1016/j.bja.2024.01.012.
  10. Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
  11. The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
  12. Efficacy and Safety of Curcumin and Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Zeng L, Yang T, Yang K, et al. Frontiers in Immunology. 2022;13:891822. doi:10.3389/fimmu.2022.891822.
  13. The Analgesic Effect of Curcumin and Nano-Curcumin in Clinical and Preclinical Studies: A Systematic Review and Meta-Analysis. Hajimirzaei P, Eyni H, Razmgir M, et al. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;398(1):393-416. doi:10.1007/s00210-024-03369-0.
  14. Curcuma as an Anti-Inflammatory Component in Treating Osteoarthritis. Koroljević ZD, Jordan K, Ivković J, Bender DV, Perić P. Rheumatology International. 2023;43(4):589-616. doi:10.1007/s00296-022-05244-8.
  15. Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
  16. Effect of Ω-3 Polyunsaturated Fatty Acids on Arthritic Pain: A systematic Review. Abdulrazaq M, Innes JK, Calder PC. Nutrition (Burbank, Los Angeles County, Calif.). 2017 Jul – Aug;39-40:57-66. doi:10.1016/j.nut.2016.12.003.
  17. Polyunsaturated Fatty Acids and Chronic Pain: A Systematic Review and Meta-Analysis. Prego-Dominguez J, Hadrya F, Takkouche B. Pain Physician. 2016 Nov-Dec;19(8):521-535.
  18. Oral Herbal Therapies for Treating Osteoarthritis. Cameron M, Chrubasik S. The Cochrane Database of Systematic Reviews. 2014;(5):CD002947. doi:10.1002/14651858.CD002947.pub2.
  19. A Standardized Boswellia Serrata Extract Shows Improvements in Knee Osteoarthritis Within Five Days-a Double-Blind, Randomized, Three-Arm, Parallel-Group, Multi-Center, Placebo-Controlled Trial. Majeed A, Majeed S, Satish G, et al. Frontiers in Pharmacology. 2024;15:1428440. doi:10.3389/fphar.2024.1428440.
  20. Effectiveness of Boswellia and Boswellia Extract for Osteoarthritis Patients: A Systematic Review and Meta-Analysis. Yu G, Xiang W, Zhang T, et al. BMC Complementary Medicine and Therapies. 2020;20(1):225. doi:10.1186/s12906-020-02985-6.
  21. Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study. Jayaram M, Kim J, Baek KS, et al. Journal of Medicinal Food. 2025;. doi:10.1177/1096620X251392467.
  22. Effectiveness of Alpha Lipoic Acid Supplementation on Biochemical, Clinical, and Inflammatory Parameters in Patients With Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. Salinas AV, Caroca TM, Santibáñez FP, et al. Diabetes & Metabolic Syndrome. 2026;20(2):103374. doi:10.1016/j.dsx.2026.103374.
  23. Evaluation of the Analgesic Effect of Ɑ-Lipoic Acid in Treating Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G. Pharmacological Research. 2022;177:106075. doi:10.1016/j.phrs.2022.106075.
  24. Oral Treatment With Alpha-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 Trial. Ziegler D, Ametov A, Barinov A, et al. Diabetes Care. 2006;29(11):2365-70. doi:10.2337/dc06-1216.
  25. 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. Bruce RD, Merlin J, Lum PJ, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017;65(10):e1-e37. doi:10.1093/cid/cix636.
  26. Effect of Resveratrol on Serum Levels of Type II Collagen and Aggrecan in Patients With Knee Osteoarthritis: A Pilot Clinical Study. Marouf BH. BioMed Research International. 2021;2021:3668568. doi:10.1155/2021/3668568.
  27. Resveratrol Supplementation Reduces Pain and Inflammation in Knee Osteoarthritis Patients Treated With Meloxicam: A Randomized Placebo-Controlled Study. Marouf BH, Hussain SA, Ali ZS, Ahmmad RS. Journal of Medicinal Food. 2018;. doi:10.1089/jmf.2017.4176.
  28. Effect of Resveratrol on Inflammatory Cytokines: A Meta-Analysis of Randomized Controlled Trials. Omraninava M, Razi B, Aslani S, et al. European Journal of Pharmacology. 2021;908:174380. doi:10.1016/j.ejphar.2021.174380.
  29. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Calverley P, Rogliani P, Papi A. Drug Safety. 2021;44(3):273-290. doi:10.1007/s40264-020-01026-y.
  30. Influence of N-Acetylcysteine on Chronic Bronchitis or COPD Exacerbations: A Meta-Analysis. Cazzola M, Calzetta L, Page C, et al. European Respiratory Review : An Official Journal of the European Respiratory Society. 2015;24(137):451-61. doi:10.1183/16000617.00002215.
  31. Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Criner GJ, Bourbeau J, Diekemper RL, et al. Chest. 2015;147(4):894-942. doi:10.1378/chest.14-1676.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.